Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment.

PubWeight™: 0.98‹?› | Rank: Top 15%

🔗 View Article (PMC 3779499)

Published in Neuropharmacology on April 29, 2013

Authors

Rebecca L Ashare1, Mary Falcone, Caryn Lerman

Author Affiliations

1: Center for Interdisciplinary Research on Nicotine Addiction, Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Suite 4100, Philadelphia, PA 19104, USA. Electronic address: rlashare@mail.med.upenn.edu.

Articles citing this

Working memory-related neural activity predicts future smoking relapse. Neuropsychopharmacology (2014) 1.02

Smoking cessation and reduction in people with chronic mental illness. BMJ (2015) 0.95

Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov (2014) 0.86

Smoking normalizes cerebral blood flow and oxygen consumption after 12-hour abstention. J Cereb Blood Flow Metab (2015) 0.82

Effects of tobacco smoke constituents, anabasine and anatabine, on memory and attention in female rats. J Psychopharmacol (2014) 0.81

Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls. Neuropsychopharmacology (2013) 0.80

Genetic Relationship between Schizophrenia and Nicotine Dependence. Sci Rep (2016) 0.80

Dissociation of tolerance and nicotine withdrawal-associated deficits in contextual fear. Brain Res (2014) 0.79

Sex differences in time perception during smoking abstinence. Nicotine Tob Res (2015) 0.79

Interoception and learning: import to understanding and treating diseases and psychopathologies. ACS Chem Neurosci (2014) 0.79

Clinical significance of early smoking withdrawal effects and their relationships with nicotine metabolism: preliminary results from a pilot study. Nicotine Tob Res (2013) 0.78

Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats. Behav Brain Res (2014) 0.78

Smoke and mirrors: The overnight abstinence paradigm as an index of disrupted cognitive function. Psychopharmacology (Berl) (2016) 0.77

ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice. Behav Pharmacol (2015) 0.77

Donepezil reverses nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6J mice. Behav Neurosci (2014) 0.77

Cognitive control deficits during mecamylamine-precipitated withdrawal in mice: Possible links to frontostriatal BDNF imbalance. Neurobiol Learn Mem (2016) 0.77

Cannabis, cigarettes, and their co-occurring use: Disentangling differences in default mode network functional connectivity. Drug Alcohol Depend (2015) 0.76

Cigarette smoking and ADHD: An examination of prognostically relevant smoking behaviors among adolescents and young adults. Psychol Addict Behav (2016) 0.75

Double dissociation of working memory and attentional processes in smokers and non-smokers with and without nicotine. Psychopharmacology (Berl) (2015) 0.75

Self-control depletion and nicotine deprivation as precipitants of smoking cessation failure: A human laboratory model. J Consult Clin Psychol (2017) 0.75

Use of an automated mobile application to assess effects of nicotine withdrawal on verbal fluency: A pilot study. Exp Clin Psychopharmacol (2016) 0.75

Transcranial Direct Current Brain Stimulation Increases Ability to Resist Smoking. Brain Stimul (2015) 0.75

Measuring cigarette smoking-induced cortical dopamine release: A [¹¹C]FLB-457 PET study. Neuropsychopharmacology (2014) 0.75

COMT polymorphism modulates the resting-state EEG alpha oscillatory response to acute nicotine in male non-smokers. Genes Brain Behav (2015) 0.75

Cognitive deficits specific to depression-prone smokers during abstinence. Exp Clin Psychopharmacol (2014) 0.75

The nature and consequences of cognitive deficits among tobacco smokers with HIV: a comparison to tobacco smokers without HIV. J Neurovirol (2017) 0.75

Articles cited by this

(truncated to the top 100)

A default mode of brain function. Proc Natl Acad Sci U S A (2001) 50.73

The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A (2005) 37.57

Working memory: looking back and looking forward. Nat Rev Neurosci (2003) 9.82

Saliency, switching, attention and control: a network model of insula function. Brain Struct Funct (2010) 9.29

N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp (2005) 9.11

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00

Self-control in decision-making involves modulation of the vmPFC valuation system. Science (2009) 8.33

A critical role for the right fronto-insular cortex in switching between central-executive and default-mode networks. Proc Natl Acad Sci U S A (2008) 7.54

Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics (1996) 6.83

Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (2006) 5.81

Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet (2004) 5.70

Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol (2008) 5.67

Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res (2007) 5.57

A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry (2011) 5.21

The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) (2002) 4.78

Remember the future: working memory training decreases delay discounting among stimulant addicts. Biol Psychiatry (2010) 3.92

Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) (2005) 3.92

The role of impulsive behavior in drug abuse. Psychopharmacology (Berl) (2008) 3.74

Behavioral impulsivity predicts treatment outcome in a smoking cessation program for adolescent smokers. Drug Alcohol Depend (2006) 3.61

Executive function and the frontal lobes: a meta-analytic review. Neuropsychol Rev (2006) 3.50

Presynaptic nicotinic ACh receptors. Trends Neurosci (1997) 3.31

Insights into the neural basis of response inhibition from cognitive and clinical neuroscience. Neurosci Biobehav Rev (2008) 3.12

Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol (1997) 3.10

Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry (1999) 2.90

It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol (2007) 2.85

Motivation and cognitive control in the human prefrontal cortex. Nat Neurosci (2009) 2.73

Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther (2006) 2.71

The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res (1988) 2.61

Predictors of smoking relapse among self-quitters: a report from the Normative Aging Study. Addict Behav (1992) 2.61

The cognitive neuroscience of sustained attention: where top-down meets bottom-up. Brain Res Brain Res Rev (2001) 2.56

Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry (2005) 2.52

Status of computerized cognitive testing in aging: a systematic review. Alzheimers Dement (2008) 2.52

Executive functions and self-regulation. Trends Cogn Sci (2012) 2.50

Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl) (2010) 2.44

Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biol Psychiatry (2005) 2.36

Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry (2008) 2.29

Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry (2005) 2.28

A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory. Neuropsychologia (1996) 2.27

Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther (2006) 2.24

Roles of accessory subunits in alpha4beta2(*) nicotinic receptors. Mol Pharmacol (2008) 2.18

Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology (2008) 2.16

Multiple neuronal networks mediate sustained attention. J Cogn Neurosci (2003) 2.15

Are the neural correlates of stopping and not going identical? Quantitative meta-analysis of two response inhibition tasks. Neuroimage (2011) 2.14

The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther (2003) 2.13

Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology (2002) 2.08

Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction (2010) 2.04

Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci (2006) 1.99

Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther (1997) 1.98

Tobacco withdrawal in self-quitters. J Consult Clin Psychol (1992) 1.94

Posterior parietal cortex and episodic retrieval: convergent and divergent effects of attention and memory. Learn Mem (2009) 1.94

Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology (2006) 1.93

Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev (2005) 1.93

The early time course of smoking withdrawal effects. Psychopharmacology (Berl) (2006) 1.90

Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci (2011) 1.83

Translational research in medication development for nicotine dependence. Nat Rev Drug Discov (2007) 1.81

Genetic architecture of smoking behavior: a study of Finnish adult twins. Twin Res Hum Genet (2006) 1.77

Cognitive mechanisms of nicotine on visual attention. Neuron (2002) 1.71

Working memory in cigarette smokers: comparison to non-smokers and effects of abstinence. Addict Behav (2005) 1.69

Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. J Neurosci (2005) 1.68

Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology (2012) 1.67

The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology (2007) 1.67

Nicotine replacement in abstinent smokers improves cognitive withdrawal symptoms with modulation of resting brain network dynamics. Neuroimage (2010) 1.66

Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev (2007) 1.62

Relapse to smoking during unaided cessation: clinical, cognitive and motivational predictors. Psychopharmacology (Berl) (2010) 1.62

Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. Psychopharmacology (Berl) (2005) 1.61

Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network. J Neurosci (2007) 1.61

The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob Res (2003) 1.57

Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray. Neuropsychopharmacology (2007) 1.56

Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend (2009) 1.53

beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53

Primary reinforcing effects of nicotine are triggered from multiple regions both inside and outside the ventral tegmental area. J Neurosci (2006) 1.52

Development of procedures for early screening of smoking cessation medications in humans. Clin Pharmacol Ther (2008) 1.51

ADHD and smoking: from genes to brain to behavior. Ann N Y Acad Sci (2008) 1.46

Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: results of a preliminary study. Psychopharmacology (Berl) (2007) 1.44

A cognitive remediation programme for adults with Attention Deficit Hyperactivity Disorder. Aust N Z J Psychiatry (2002) 1.43

Brain activity in cigarette smokers performing a working memory task: effect of smoking abstinence. Biol Psychiatry (2005) 1.43

Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. Mol Psychiatry (2008) 1.43

Nicotine self-medication of cognitive-attentional processing. Addict Biol (2008) 1.42

Attention deficit hyperactivity disorder symptoms predict nicotine dependence and progression to regular smoking from adolescence to young adulthood. J Pediatr Psychol (2007) 1.42

The effects of DHBE and MLA on nicotine-induced enhancement of contextual fear conditioning in C57BL/6 mice. Psychopharmacology (Berl) (2005) 1.39

Maze procedures: the radial-arm and water maze compared. Brain Res Cogn Brain Res (1996) 1.39

Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry (2010) 1.38

Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol (2009) 1.37

Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. Neurobiol Learn Mem (2011) 1.37

Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology (2006) 1.36

Preliminary evidence of the association between the history of childhood attention-deficit/hyperactivity disorder and smoking treatment failure. Nicotine Tob Res (2005) 1.36

Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (2011) 1.33

Genetic analyses of DSM-IV nicotine withdrawal in adult twins. Psychol Med (2006) 1.32

Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology (Berl) (2011) 1.31

Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. Pharmacol Biochem Behav (2007) 1.29

Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy. J Subst Abuse Treat (2005) 1.28

Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clin Pharmacol Ther (2010) 1.26

Methylphenidate increases cigarette smoking. Psychopharmacology (Berl) (2005) 1.23

C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry (2004) 1.23

Smoking cessation and inattention or hyperactivity/impulsivity: a post hoc analysis. Nicotine Tob Res (2008) 1.22

Smoking patterns and abstinence effects in smokers with no ADHD, childhood ADHD, and adult ADHD symptomatology. Addict Behav (2003) 1.21

Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology (2008) 1.21

Cigarette smoking associated with attention deficit hyperactivity disorder. J Pediatr (2008) 1.19

Impact of smoking abstinence on working memory neurocircuitry in adolescent daily tobacco smokers. Psychopharmacology (Berl) (2007) 1.18

Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. Biochem Pharmacol (2011) 1.17

Articles by these authors

(truncated to the top 100)

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38

Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol (2004) 3.88

Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry (2008) 3.12

Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med (2010) 2.94

Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry (2008) 2.29

Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A (2003) 2.29

Association of attention-deficit/hyperactivity disorder symptoms with levels of cigarette smoking in a community sample of adolescents. J Am Acad Child Adolesc Psychiatry (2002) 2.19

Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol (2002) 2.13

Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet (2008) 2.12

Neural substrates of abstinence-induced cigarette cravings in chronic smokers. J Neurosci (2007) 2.11

Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet (2009) 2.07

All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet (2002) 2.05

Gender differences in acute tobacco withdrawal: effects on subjective, cognitive, and physiological measures. Exp Clin Psychopharmacol (2007) 1.94

A randomized controlled trial of financial incentives for smoking cessation. Cancer Epidemiol Biomarkers Prev (2006) 1.93

Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav (2008) 1.90

New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. Drug Alcohol Depend (2006) 1.85

Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A (2009) 1.76

The use of race variables in genetic studies of complex traits and the goal of reducing health disparities: a transdisciplinary perspective. Am Psychol (2005) 1.71

Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology (2003) 1.70

Cigarette smoking practices among American college students: review and future directions. J Am Coll Health (2004) 1.69

A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol (2002) 1.69

Relationship between education and delay discounting in smokers. Addict Behav (2004) 1.65

Assessing dimensions of nicotine dependence: an evaluation of the Nicotine Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking Dependence Motives (WISDM). Nicotine Tob Res (2008) 1.62

Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology (Berl) (2005) 1.62

Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. J Gen Intern Med (2005) 1.54

Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend (2009) 1.53

Non-replication of genetic association studies: is DAT all, folks? Nicotine Tob Res (2002) 1.50

Interacting effects of genetic predisposition and depression on adolescent smoking progression. Am J Psychiatry (2004) 1.50

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry (2007) 1.48

Colon cancer screening practices following genetic testing for hereditary nonpolyposis colon cancer (HNPCC) mutations. Arch Intern Med (2004) 1.48

Parent-child factors and their effect on communicating BRCA1/2 test results to children. Patient Educ Couns (2002) 1.47

CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry (2007) 1.44

Comparison between two measures of delay discounting in smokers. Exp Clin Psychopharmacol (2003) 1.42

Food hedonics and reinforcement as determinants of laboratory food intake in smokers. Physiol Behav (2004) 1.41

Initial nicotine sensitivity in humans as a function of impulsivity. Psychopharmacology (Berl) (2008) 1.40

Facilitating transdisciplinary research: the experience of the transdisciplinary tobacco use research centers. Nicotine Tob Res (2003) 1.39

Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol (2003) 1.38

Smoking topography predicts abstinence following treatment with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev (2004) 1.38

Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry (2010) 1.38

An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res (2007) 1.37

Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs (2006) 1.35

Behavioral consequences of testing for obesity risk. Cancer Epidemiol Biomarkers Prev (2005) 1.35

Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers. Am J Clin Nutr (2004) 1.34

Individual differences in nicotine intake per cigarette. Cancer Epidemiol Biomarkers Prev (2003) 1.32

Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A (2011) 1.29

Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy. J Subst Abuse Treat (2005) 1.28

Influence of methylphenidate on eating in obese men. Obes Res (2004) 1.27

Association of retrospective early smoking experiences with prospective sensitivity to nicotine via nasal spray in nonsmokers. Nicotine Tob Res (2008) 1.27

Evidence for endogenous formation of N'-nitrosonornicotine in some long-term nicotine patch users. Nicotine Tob Res (2009) 1.27

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res (2007) 1.26

Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev (2005) 1.24

Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics (2013) 1.24

Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res (2004) 1.24

Treating tobacco dependence in women. J Womens Health (Larchmt) (2007) 1.23

Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav Pharmacol (2008) 1.22

Experimental evaluation of antitobacco PSAs: effects of message content and format on physiological and behavioral outcomes. Nicotine Tob Res (2009) 1.21

Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res (2007) 1.21

Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. Nicotine Tob Res (2005) 1.20

Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry (2006) 1.18

Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacology (2010) 1.17

Characteristics of cancer patients entering a smoking cessation program and correlates of quit motivation: implications for the development of tobacco control programs for cancer patients. Psychooncology (2004) 1.17

Reduced prefrontal and temporal processing and recall of high "sensation value" ads. Neuroimage (2009) 1.17

Facilitating clinical implementation of pharmacogenomics. JAMA (2011) 1.16

The effect of smoking cues in antismoking advertisements on smoking urge and psychophysiological reactions. Nicotine Tob Res (2009) 1.15

Nicotine vaccines: will smokers take a shot at quitting? Nicotine Tob Res (2010) 1.15

Evaluating smokers' reactions to advertising for new lower nicotine quest cigarettes. Psychol Addict Behav (2006) 1.15

Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology (2011) 1.15

Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics (2005) 1.13

Narrative Health Communication and Behavior Change: The Influence of Exemplars in the News on Intention to Quit Smoking. J Commun (2012) 1.13

The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev (2013) 1.13

Associations between Cloninger's temperament dimensions and acute tobacco withdrawal. Addict Behav (2007) 1.13

Primary care physicians' willingness to offer a new genetic test to tailor smoking treatment, according to test characteristics. Nicotine Tob Res (2008) 1.12

A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients. Ann Behav Med (2005) 1.12

Identification of pharmacogenetic markers in smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet (2008) 1.12

Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics (2005) 1.11

Variability in initial nicotine sensitivity due to sex, history of other drug use, and parental smoking. Drug Alcohol Depend (2008) 1.10

Genetics and smoking behavior. Curr Psychiatry Rep (2007) 1.09

Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation. J Subst Abuse Treat (2007) 1.08

Smoking cues, argument strength, and perceived effectiveness of antismoking PSAs. Nicotine Tob Res (2011) 1.07

Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. Behav Neurosci (2008) 1.07

Reduced nicotine reward in obesity: cross-comparison in human and mouse. Psychopharmacology (Berl) (2005) 1.05

Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer. Breast Cancer Res Treat (2002) 1.04

Dopamine genes and nicotine dependence in treatment-seeking and community smokers. Neuropsychopharmacology (2009) 1.04

Do small lapses predict relapse to smoking behavior under bupropion treatment? Nicotine Tob Res (2004) 1.03

The STAGE cohort: a prospective study of tobacco use among Swedish twins. Nicotine Tob Res (2008) 1.02

Intergenerational transmission of tobacco use and dependence: a transdisciplinary perspective. Nicotine Tob Res (2003) 1.01

Smoking in response to negative mood in men versus women as a function of distress tolerance. Nicotine Tob Res (2012) 1.00

Predictors of attendance in a randomized clinical trial of nicotine replacement therapy with behavioral counseling. Drug Alcohol Depend (2003) 1.00

Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev (2002) 0.99

Predictors of participation in psychosocial telephone counseling following genetic testing for BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev (2004) 0.98

A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend (2008) 0.98

CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev (2007) 0.98

Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev (2006) 0.98

Effects of different nicotine replacement therapies on postcessation psychological responses. Addict Behav (2005) 0.98

The types of regular cigarette smokers: a latent class analysis. Nicotine Tob Res (2005) 0.97

Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology (Berl) (2005) 0.97

Predictors of cognitive appraisals following genetic testing for BRCA1 and BRCA2 mutations. J Behav Med (2004) 0.96

Age-related differences in working memory deficits during nicotine withdrawal. Addict Biol (2013) 0.96

Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch. Cancer Epidemiol Biomarkers Prev (2009) 0.96

Content matters: neuroimaging investigation of brain and behavioral impact of televised anti-tobacco public service announcements. J Neurosci (2013) 0.95